{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"Pluri Inc."},"Symbol":{"label":"Symbol","value":"PLUR"},"Address":{"label":"Address","value":"MATAM ADVANCED TECHNOLOGY PARK,BUILDING NO.5, HAIFA, 3508409, Israel"},"Phone":{"label":"Phone","value":"+972 747108600"},"Industry":{"label":"Industry","value":"Biotechnology: Biological Products (No Diagnostic Substances)"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"Middle East"},"CompanyDescription":{"label":"Company Description","value":"Pluristem Therapeutics Inc is registered with the U.S. Security and Exchange Commission and incorporated in the state of Nevada. Pluristem Therapeutics Inc is primarely in the business of biological products (no diagnostic substances). For financial reporting, their fiscal year ends on June 30th. This page includes all SEC registration details as well as a list of all documents (S-1, Prospectus, Current Reports, 8-K, 10K, Annual Reports) filed by Pluristem Therapeutics Inc. Pluristem Therapeutics Inc is a US-based company which acts as a developer of placenta-based cell therapy product candidates for the treatment of multiple ischemic, inflammatory and hematologic conditions. The lead indications are critical limb ischemia, recovery after surgery for femoral neck fracture, and acute radiation syndrome. The company operations are focused on the research, development, clinical trials and manufacturing of cell therapeutics and related technologies."},"CompanyUrl":{"label":"Company Url","value":"https://www.pluri-biotech.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Artur Machlenkin","title":"Chief Scientific Officer"},{"name":"Lior Raviv","title":"Chief Technology Officer"},{"name":"Michal Sheleg","title":"VP-Clinical Development"},{"name":"Yaky Yanay","title":"President, Chief Executive Officer & Director"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}